Agile Therapeutics, Inc.

AGRX

US00847L3087

Biotechnology & Medical Research

Market Closed - OTC Markets Other stock markets 02:00:26 2024-04-25 pm EDT			5-day change	1st Jan Change
0.4 ^USD	-0.07%		+8.11%	-79.49%

Mar. 28	Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28	Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	MT

Agile Therapeutics, Inc. announced that it has received $45 million in funding from Perceptive Advisors LLC

March 28, 2021

On March 1, 2021, the company amended the terms of the transaction. The company now raised $45 million in the transaction. The investor provided additional $10 million in its fourth tranche close.

Latest news about Agile Therapeutics, Inc.

Transcript : Agile Therapeutics, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q4 Revenue $3.6M	Mar. 28	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from S&P TMI Index	Mar. 27	CI
Agile Therapeutics, Inc.(OTCPK:AGRX) dropped from NASDAQ Composite Index	Mar. 24	CI
North American Morning Briefing : Stocks Struggle After New Records	Mar. 22	DJ
North American Morning Briefing : Stock Futures -2-	Mar. 19	DJ
Maxim Downgrades Agile Therapeutics to Hold From Buy	Mar. 18	MT
Agile Therapeutics Inc. Completes Pay-Off the Remainder of its Debt Facility	Mar. 14	CI
Top Premarket Gainers	Feb. 22	MT
Agile Therapeutics, Inc. Announces Senior Secured Term Loan Credit Facility of Up to $35.0 Million	Feb. 15	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Full Year Ended December 31, 2023	Feb. 15	CI
Agile Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Agile Therapeutics, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Agile Therapeutics, Inc. Reaffirms Revenue Guidance for the Full Year 2023	Nov. 09	CI
Earnings Flash (AGRX) AGILE THERAPEUTICS Reports Q3 Revenue $6.7M, vs. Street Est of $6.35M	Nov. 09	MT
North American Morning Briefing : Traders Await -2-	Nov. 09	DJ
North American Morning Briefing : Stock Futures -2-	23-09-25	DJ
Maxim Upgrades Agile Therapeutics to Buy From Hold With $5 Price Target	23-09-22	MT
Agile Therapeutics, Inc. Affirms Revenue Guidance for the Year 2023	23-08-09	CI
Transcript : Agile Therapeutics, Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Earnings Flash (AGRX) AGILE THERAPEUTICS Posts Q2 Revenue $5.5M	23-08-09	MT
Agile Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Agile Therapeutics, Inc. Provides Revenue Guidance for the Year 2023	23-06-30	CI
Agile Therapeutics, Inc. Announces Executive Changes	23-06-27	CI

Chart Agile Therapeutics, Inc.

Duration

Period

More charts

Agile Therapeutics, Inc. is a women's healthcare company, which is engaged in fulfilling the unmet health needs of women. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.

Sector

Biotechnology & Medical Research

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

	1st Jan change	Capi.
AGILE THERAPEUTICS, INC.	-79.49%	2.74M
VERTEX PHARMACEUTICALS INCORPORATED	-2.26%	104B
REGENERON PHARMACEUTICALS, INC.	+1.41%	97.42B
ARGENX SE	+0.79%	22.2B
BIONTECH SE	-17.84%	21.23B
GENMAB A/S	-11.11%	18.33B
WUXI APPTEC CO., LTD.	-42.83%	16.35B
BEIGENE, LTD.	-17.63%	15.06B
NEUROCRINE BIOSCIENCES, INC.	+4.55%	13.98B
SAREPTA THERAPEUTICS, INC.	+32.11%	11.66B

Bio Therapeutic Drugs